Artificial Intelligence Could Improve IVF Outcomes

A study conducted in 2017 forecasted that artificial intelligence (AI) could extensively improve health-care results by 30–40%. AiVF, an Israeli ML company, has suggested that artificial intelligence bears the potential to grow the success rate of IVF by almost three times when compared to conventional methods. It should be noted, however, that pregnancy is dependent on other factors, such as age.

IVF, or in vitro-fertilization, is a series of procedures that involves the extraction of mature ova from a woman’s body, which are then fertilized in a lab setting with sperm in a liquid. The fertilized ovum is then implanted back into the woman’s body. This procedure, which is an example of assisted reproductive technology (ART), is usually recommended to couples who are struggling to conceive.

According to an American Society for Reproductive Medicine report that was released last year, there are 7.3 million women dealing with infertility in the United States. Every year, roughly 2.7 million in vitro fertilization cycles are carried out. Unfortunately, a study published in the “Acta Informatica Medica” journal reports that the overall rate of success of conventional-assisted reproductive technology methods is below 30%.

AiVF provides fertility services that include using computer vision technology and machine learning to assist embryologists to find embryos that are most likely to successfully implant during intrauterine implantation. The company plans to set up commercially this year and is currently working with eight facilities to conduct clinical trials around the world, including in the the United States, Europe and Israel.

Ron Maor, the company’s head of algorithm research, explained that AiVF  had developed its own custom layer on various industry-standard machine learning, deep learning and artificial intelligence applications. He added that the tools manage both unusual and specific features of embryo images, which differ greatly from a majority of artificial intelligence tasks.

The company’s machine learning technique involves the creation of time-lapse videos of embryos developing in an incubator. Daniella Gilboa, the firm’s CEO, explained that an analysis of the videos is then conducted to unearth many features and milestones that cannot be detected by the human eye. This information then helps teach an algorithm what a successful embryo is.

In addition, Gilboa noted that one embryo in every ten could be implanted in a patient’s uterus, explaining that an embryologist would know in a two-week period whether the patient was pregnant.

The company’s initial results suggest that machine learning and computer vision could help reduce the price of IVF, which would make it less burdensome and expensive for a woman to conceive.

Still on the subject of state-of-the-art tech, Brain Scientific Inc. (OTCQB: BRSF) has two devices that are approved by the FDA and have patents protecting them in China, Europe and the United States. Those devices help neurologists diagnose patients quickly and affordably, unlike the EEG technology that has been the go-to tech in neurology.

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.